| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Feb 5, 2018 | NBIX Neurocrine Biosciences Inc | Benevich Eric62 | Chief Commercial Officer | Sell | 820 | $83.14 | $68,174.23 | -24.1% | |
| Feb 5, 2018 | PBH Prestige Consumer Healthcare Inc. | Costley Gary E | Director | Buy | 7,500 | $35.47 | $266,025.00 | +24.2% | |
| Feb 5, 2018 | NBIX Neurocrine Biosciences Inc | Lippoldt Darin60 | Chief Legal Officer | Sell | 2,737 | $83.12 | $227,494.37 | -9.0% | |
| Feb 5, 2018 | NBIX Neurocrine Biosciences Inc | Bozigian Haig P. | Chief Development Officer | Sell | 2,262 | $83.10 | $187,976.53 | -0.8% | |
| Feb 5, 2018 | LLY Eli Lilly & Co | Zakrowski Donald A | Chief Accounting Officer | Sell | 900 | $81.09 | $72,981.00 | -17.9% | |
| Feb 5, 2018 | PBH Prestige Consumer Healthcare Inc. | Lombardi Ronald M.52 | Chief Executive Officer | Buy | 7,000 | $35.94 | $251,580.00 | +5.3% | |
| Feb 5, 2018 | NBIX Neurocrine Biosciences Inc | Lloyd-Smith Malcolm49 | Chief Regulatory Officer | Sell | 960 | $83.19 | $79,862.59 | -6.4% | |
| Feb 5, 2018 | NBIX Neurocrine Biosciences Inc | Obrien Christopher Flint | Former Chief Medical Officer | Sell | 2,613 | $83.18 | $217,341.46 | -2.4% | |
| Feb 5, 2018 | PBH Prestige Consumer Healthcare Inc. | Jenness James M | Director | Buy | 4,200 | $35.47 | $148,974.00 | +60.9% | |
| Feb 5, 2018 | LLY Eli Lilly & Co | Simmons Jeffrey N52 | SVP&Pres. Elanco Animal Health | Sell | 9,625 | $81.12 | $780,780.00 | -6.7% | |
| Feb 2, 2018 | ALKS Alkermes Plc. | Cooke Shane62 | President, Alkermes Plc | Sell | 72,793 | $60.55 | $4,407,679.38 | -30.1% | |
| Feb 1, 2018 | CANN Trees Corp (colorado) | Frichtel Robert Lawrence | Chief Executive Officer | Sell | 50,000 | $3.93 | $196,704.50 | -1.4% | |
| Feb 1, 2018 | ALKS Alkermes Plc. | Mitchell Paul J | Director | Sell | 1,000 | $56.77 | $56,770.00 | -11.1% | |
| Feb 1, 2018 | MRMD Marimed Inc. | Kidrin Thomas | Director | Sell | 300,000 | $1.22 | $365,000.00 | -5.1% | |
| Jan 31, 2018 | AMRN Amarin Corp Plc\uk | Kennedy Joseph T | General Counsel | Sell | 44,857 | $3.73 | $167,388.38 | -70.9% | |
| Jan 29, 2018 | ALKS Alkermes Plc. | Cooke Shane62 | President, Alkermes Plc | Sell | 5,000 | $60.01 | $300,027.88 | -3.2% | |
| Jan 26, 2018 | AMPH Amphastar Pharmaceuticals, Inc. | Shandell Jason B. | President And General Counsel | Sell | 18,627 | $19.42 | $361,747.11 | -4.0% | |
| Jan 25, 2018 | ESPR Esperion Therapeutics, Inc. | Vitullo Nicole | Director | Sell | 11,674 | $71.79 | $838,076.46 | -43.2% | |
| Jan 24, 2018 | IRWD Ironwood Pharmaceuticals Inc | Currie Mark G53 | Chief Scientific Officer | Sell | 60,000 | $15.45 | $927,000.00 | -7.2% | |
| Jan 24, 2018 | NBIX Neurocrine Biosciences Inc | Rastetter William H48 | Director | Sell | 9,500 | $90.00 | $855,000.00 | -27.7% | |
| Jan 23, 2018 | AMRN Amarin Corp Plc\uk | Ketchum Steven B | Chief Scientific Officer | Sell | 135,205 | $4.41 | $596,429.82 | -48.8% | |
| Jan 23, 2018 | EBS Emergent Biosolutions Inc. | Hauer Jerome M | Director | Sell | 7,729 | $50.69 | $391,786.69 | -18.2% | |
| Jan 23, 2018 | COLL Collegium Pharmaceutical, Inc | Heffernan Michael Thomas | Chairman, President And CEO | Sell | 20,000 | $25.01 | $500,164.08 | -1.9% | |
| Jan 22, 2018 | SUPN Supernus Pharmaceuticals, Inc. | Bhatt Padmanabh P.69 | Sr. VP Of Ip, CSO | Sell | 20,000 | $48.04 | $960,716.00 | -61.5% | |
| Jan 19, 2018 | COLL Collegium Pharmaceutical, Inc | Heffernan Michael Thomas | Chairman, President And CEO | Sell | 20,000 | $22.50 | $450,000.00 | -3.6% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.